Tissue plasminogen activator for treatment of fibrin in endophthalmitis.
Damji
K F
KF
University of Ottawa Eye Institute, ON. kdamji@hotmail.com
O'Connor
M D
MD
Hill
V
V
D000368:Aged; D000867:Anterior Chamber / Q000187:drug effects; D000900:Anti-Bacterial Agents; D002387:Cataract Extraction; D004359:Drug Therapy, Combination / Q000627:therapeutic use; D009877:Endophthalmitis / Q000188:drug therapy* / Q000382:microbiology; D015818:Eye Infections, Bacterial / Q000188:drug therapy* / Q000382:microbiology; D005260:Female; D005337:Fibrin / Q000187:drug effects*; D005342:Fibrinolysis / Q000187:drug effects; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006801:Humans; D007267:Injections; D019654:Lens Implantation, Intraocular; D008297:Male; D011183:Postoperative Complications / Q000188:drug therapy* / Q000382:microbiology; D013203:Staphylococcal Infections / Q000188:drug therapy* / Q000382:microbiology; D013210:Staphylococcus / Q000302:isolation & purification; D010959:Tissue Plasminogen Activator / Q000627:therapeutic use*; D014822:Vitreous Body / Q000382:microbiology
D000900:Anti-Bacterial Agents; D005343:Fibrinolytic Agents; D005337:Fibrin; D010959:Tissue Plasminogen Activator